Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed stage I-II adenocarcinoma of the prostate
• * At least 6 weeks since prior biopsy
• Scheduled to undergo radical prostatectomy within 6 months of MRI and magnetic resonance spectroscopic imaging (MRSI)
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Not specified
• Life expectancy:
• Not specified
• Hematopoietic:
• Not specified
• Hepatic:
• Not specified
• Renal:
• Not specified
• Cardiovascular:
• No cardiac pacemakers
• Other:
• Must be willing and able to undergo MRI/MRSI
• No allergy to latex
• No contraindications to MRI such as non-compatible intracranial vascular clips
• No metallic hip implant or any other metallic implant or device that would compromise quality of MRI/MRSI
• No contraindications to or intolerance of endorectal coil insertion (e.g., prior abdominoperineal resection of the rectum or Crohn's disease)
• No general medical or psychiatric condition or physiologic status unrelated to prostate cancer that would preclude valid informed consent
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior BCG for bladder cancer
• Chemotherapy:
• Not specified
• Endocrine therapy:
• No prior androgen-deprivation therapy
• Radiotherapy:
• No prior prostatic or rectal radiotherapy
• Surgery:
• See Disease Characteristics
• No prior cryosurgery
• No prior surgery for prostate cancer
• No prior transurethral resection of the prostate (TURP)
• No prior rectal surgery
• Other:
• No prior complementary alternative medicine